ACRS - Why Is Arthritis-Focused Aclaris Therapeutics Stock Nosediving Today? | Benzinga
Aclaris Therapeutics Inc (NASDAQ: ACRS) shares plunged after the company released topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.
The study evaluated two doses of zunsemetinib plus methotrexate (MTX) versus placebo plus MTX in patients with moderate to severe RA who have had an inadequate response to MTX alone.
The ...